These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 36031684)
1. Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod. Morillos MB; de Aguiar PHP; Franceschini PR; Duarte JÁ; Piccini CD; Finkelsztejn A Neurol Sci; 2023 Jan; 44(1):361-363. PubMed ID: 36031684 [TBL] [Abstract][Full Text] [Related]
2. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod. Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114 [TBL] [Abstract][Full Text] [Related]
3. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574 [TBL] [Abstract][Full Text] [Related]
4. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. Papathemeli D; Gräfe R; Hildebrandt U; Zettl UK; Ulrich J Mult Scler; 2016 Dec; 22(14):1888-1890. PubMed ID: 27207455 [TBL] [Abstract][Full Text] [Related]
6. Listeria monocytogenes rhombencephalitis in a patient with multiple sclerosis during fingolimod therapy. Tecellioglu M; Kamisli O; Kamisli S; Erdogmus UA; Özcan C Mult Scler Relat Disord; 2019 Jan; 27():409-411. PubMed ID: 30530070 [TBL] [Abstract][Full Text] [Related]
7. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis. Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568 [TBL] [Abstract][Full Text] [Related]
8. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings. Chong I; Wang KY; Lincoln CM Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079 [TBL] [Abstract][Full Text] [Related]
9. Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review. Kawai H; Matsushita H; Akashi H; Furuya D; Kawakami S; Suzuki R; Moriuchi M; Ogawa Y; Kawada H; Nakamura N; Ando K Leuk Lymphoma; 2020 Apr; 61(4):959-962. PubMed ID: 31773997 [No Abstract] [Full Text] [Related]
10. Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature. Najdaghi S; Davani DN; Ghajarzadeh M; Shaygannejad V Autoimmun Rev; 2022 Dec; 21(12):103203. PubMed ID: 36220524 [No Abstract] [Full Text] [Related]
11. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis. Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666 [TBL] [Abstract][Full Text] [Related]
12. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Samaraweera AP; Cohen SN; Akay EM; Evangelou N Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664 [TBL] [Abstract][Full Text] [Related]
13. Soft Palate Malignant Melanoma as an Adverse Effect of Fingolimod in Multiple Sclerosis: A Case Report and Literature Review. Mozhdehipanah H; Safdarian F; Paybast S Neurol India; 2023; 71(3):546-548. PubMed ID: 37322755 [TBL] [Abstract][Full Text] [Related]
14. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod. Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493 [No Abstract] [Full Text] [Related]
15. Fingolimod (Gilenya) and melanoma. Robinson CL; Guo M BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 28003234 [TBL] [Abstract][Full Text] [Related]
16. Cerebral toxoplasmosis in an MS patient receiving Fingolimod. Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790 [TBL] [Abstract][Full Text] [Related]
17. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis. Christopher KL; Elner VM; Demirci H Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512 [TBL] [Abstract][Full Text] [Related]
18. Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod. Cheraghmakani H; Nasehi MM; Baghbanian SM Mult Scler Relat Disord; 2019 Aug; 33():116-120. PubMed ID: 31185372 [TBL] [Abstract][Full Text] [Related]
19. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Cuascut FX; Alkabie S; Hutton GJ Mult Scler Relat Disord; 2021 Aug; 53():103072. PubMed ID: 34139459 [TBL] [Abstract][Full Text] [Related]
20. Fingolimod-Associated Intracerebral Lymphoproliferative Disorder. Baharnoori M; Mahajan R; Solomon IH; Pinkus G; Houtchens M Am J Ther; 2019; 26(4):e481-e484. PubMed ID: 29189316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]